FIELD: medicine.
SUBSTANCE: invention is referred to medicine, in particular to experimental pharmacology. For realisation of risk prediction method of ulceration of gastroduodenal zone tissues, determine lipide structure of a blood plasma. Thus, the high risk of ulceration is defined at level of phospholipids 23.18±1.30% cholesterol 15.53±0.87%, and ethers of cholesterol 39.71±1.38%. The low risk of ulceration is defined at level of phospholipids 28.03±1.58%, cholesterol 22.36±1.22%, and ethers of cholesterol 33.04±2.33%. Tests of preparations with counter-ulcerogenic activity are recommended to be spent on the rats predisposed to an ulceration that allows estimating more objectively counter-ulcerogenic activity of tested preparations.
EFFECT: obtaining an effective way of risk predicition of gastroduodenal zone tissues ulceration.
7 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREDICTING RISK OF MUCOSAL ULCERATION OF STOMACH | 2008 |
|
RU2391666C1 |
METHOD OF PRIMARY PREVENTION OF ULCERATIVE DUODENUM DISORDERS AND DEVELOPMENT THEREOF | 2006 |
|
RU2348414C2 |
STRESS PROTECTOR | 2009 |
|
RU2414921C1 |
HEPATOPROTECTIVE AGENT FROM ALGAE | 2013 |
|
RU2528898C1 |
3-[3-(MORPHOLINE-4-YL)PROPYL]-2-[(2,2,3-TRIMETHYLCYCLOPENT-3-ENE-1-YL)METHYL-1,3-THIAZOLIDINE-4-ONE WITH ANTI-ULCER AND ANTI-INFLAMMATORY ACTIVITY | 2017 |
|
RU2643669C1 |
METHYL ETHER (± ) 7-[2β-[1-AMINO-3-OXO-4-ACETOXI-(1E)-BUTENYL]-5-OXOCYCLOPENTYL-1a]HETANOIC ACID POSSESSING ANTIULCEROUS ACTIVITY | 1983 |
|
SU1221871A1 |
GASTROPROTECTIVE MEDICATION | 2009 |
|
RU2406520C2 |
METHOD OF COMBINED TREATMENT OF DUODENAL ULCER IN COMORBID PATHOLOGY | 2019 |
|
RU2723212C1 |
MEDICINAL AGENT AND METHOD OF TREATMENT OF EROSIVE AND INFLAMMATORY DISEASES OF GASTROENTERIC TRACT | 2001 |
|
RU2197266C1 |
METHOD FOR TREATING CHOLELITHIASIS PATIENTS FOR HYPERCHOLESTEROLEMIA STATES BY ADMINISTERING HEPATOSAN PREPARATION ACCELERATING CHOLESTEROL OXIDATION IN LIVER | 2006 |
|
RU2306943C1 |
Authors
Dates
2008-10-27—Published
2006-12-25—Filed